281 related articles for article (PubMed ID: 15185348)
1. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY
Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
3. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
[TBL] [Abstract][Full Text] [Related]
5. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
[TBL] [Abstract][Full Text] [Related]
6. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
8. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.
De Giovanni C; Nicoletti G; Palladini A; Croci S; Landuzzi L; Antognoli A; Murgo A; Astolfi A; Ferrini S; Fabbi M; Orengo AM; Amici A; Penichet ML; Aurisicchio L; Iezzi M; Musiani P; Nanni P; Lollini PL
Hum Gene Ther; 2009 May; 20(5):453-64. PubMed ID: 19215191
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
Pakravan N; Hashemi SM; Hassan ZM
Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
12. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
14. CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.
Nguyen-Hoai T; Baldenhofer G; Ahmed MS; Pham-Duc M; Gries M; Lipp M; Dörken B; Pezzutto A; Westermann J
J Gene Med; 2012 Feb; 14(2):128-37. PubMed ID: 22228591
[TBL] [Abstract][Full Text] [Related]
15. RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency.
Wang ST; Chang CC; Yen MC; Tu CF; Chu CL; Peng YT; Chen DY; Lan JL; Lin CC
Gene Ther; 2011 Apr; 18(4):372-83. PubMed ID: 21107437
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu as a target for cancer vaccines.
Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
[TBL] [Abstract][Full Text] [Related]
17. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.
Disis ML; Shiota FM; McNeel DG; Knutson KL
Immunobiology; 2003; 207(3):179-86. PubMed ID: 12777059
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
Saha A; Chatterjee SK
Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.
Chen Y; Hu D; Eling DJ; Robbins J; Kipps TJ
Cancer Res; 1998 May; 58(9):1965-71. PubMed ID: 9581840
[TBL] [Abstract][Full Text] [Related]
20. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
